secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medtronic plc (MDT)
CIK:        0001613103
Form:       8-K
Filed at:   2021-08-24T23:59:59+00:00
Accession:  0001613103-21-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medtronic Q1 FY22 revenue $7.99B (+23% reported), non-GAAP EPS $1.41, beats expectations; raises FY22 EPS guidance
--------------------------------------------------------------------------------

- Revenue $7.987B, up 23% reported and 19% organic; GAAP EPS $0.56, non-GAAP EPS $1.41.
- Cardiovascular revenue $2.89B (+15% organic); Medical Surgical $2.32B (+25% organic); Neuroscience $2.20B (+26% organic).
- Diabetes revenue $572M declined 3% organic; U.S. consumables and CGM sales fell mid-teens.
- FY22 organic revenue growth reiterated at ~9%; non-GAAP EPS guidance raised to $5.65-$5.75 from $5.60-$5.75.
- CEO Geoff Martha cites procedure recovery and share gains; company repurchasing shares and increasing R&D spend.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613103/000161310321000037/0001613103-21-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613103/000161310321000037/mdt-20210824.htm
  HTML page:      https://secwatch.observer/filing/0001613103-21-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer